Article in Leukemia & lymphoma, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 1 institution in 1 country.
Alyce M KuoDermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-6780-6506
Hani HassounMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Urvi ShahMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Allison GordonDermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Travis J HollmannDermatopathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Heather J LandauAdult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-3152-1189
Cecilia LezcanoDermatopathology Service, Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sham MailankodyMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Carlyn C TanMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Alexander M LesokhinMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-9321-702X
Alina MarkovaDermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-2427-3199
Memorial Sloan Kettering Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
MSK Paul Calabresi Career Development Award for Clinical OncologyK12CA184746 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Omar Abdel-Wahab, Simon N. Powell · 2015 to 2026
$8.3M
Supervised Learning in the Auditory SystemF31DC008748 · NIDCD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI NICHOLS, GRANT S · 2007 to 2009
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Dupilumab for the treatment of refractory lenalidomide rash in patients with multiple myeloma. · full record | OpenQuestion